Hong Kong Exchanges and Clearing Limited

FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation

Form Serial Number:

DA20211129E00175

1. Date of relevant event:

24/11/2021
(dd/mm/yyyy)

2. Date when director became aware of the relevant event/ interest in the shares (if later):

(dd/mm/yyyy)

3. Stock code:

01548

4. Name of listed corporation:

Genscript Biotech Corporation

5. Class of shares:

Ordinary Shares

6. Number of issued shares in class:

2,100,504,082

7. Name of director (English) as printed on HKID Card/Passport:

(Surname)	Zhu
(Other names)	Li

10. Name of director (Chinese):

朱力

11. Chinese Character Code as printed on HKID Card:

26120500

24. Details of relevant event:

Brief description of relevant event

Capacity in which shares were/are held

Number of shares bought/sold or involved

Currency of transaction

On Exchange

Off Exchange

Before relevant event

After relevant event

Highest price (per share)

Average price (per share)

Average consideration (per share)

Consideration code

Long position

1201	The number of shares in which you are interested has reduced because: you completed a sale of the shares

2101	Beneficial owner

57,514

HKD

37.3286

Short position

25. Total shares in listed corporation immediately before the relevant event:

	Total number of shares	Percentage figure (%)
Long position	2,381,597	0.11

26. Total shares in listed corporation immediately after the relevant event:

	Total number of shares	Percentage figure (%)
Long position	2,324,083	0.11

27. Capacity in which interests disclosed in Box 26 are held:

Code describing capacity

Number of shares

2101	Beneficial owner

Long position

2,324,083

28. Further information in derivative interests in listed corporation :

Derivatives code

Exercise period (dd/mm/yyyy)

Consideration - if derivatives granted by listed corporation

Number of shares

Begins

Ends

Currency

Price for grant

Currency

Exercise price

Currency

Price on assignment

Long position

4105	Unlisted derivatives - Physically settled

11/10/2017

10/10/2027

HKD

1.00

HKD

8.330

800,000

Long position

4108	Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)

200,000

Long position

4108	Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)

100,000

29. Further information in relation to interests of children under 18 and/or spouse:

Child/Spouse	Name of child/spouse	Number of shares

30. Further information in relation to interests of corporations controlled by Director:

Name of controlled corporation	Address and place of incorporation	Name of controlling person	% control	Direct interest (Y/N)	Number of shares

31. Further information in relation to interests held by Director jointly with another person:

Name of joint shareholder	Address	Number of shares

32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:

Names of Trust	Address	Status code	Number of shares

33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):

Names of other parties	Address	Number of shares

Total number of shares in which a director is interested under sections 317 and 318

34. Supplementary information:

Dr. Zhu Li was granted restricted shares underlying 200,000 shares of Genscript Biotech Corporation (the "Company") on 28 December 2020 that will vest in five annual installments equally on 27 December 2021 to 27 December 2025. Dr. Zhu Li was granted restricted shares underlying 100,000 shares of the Company on 31 May 2021 that will vest in five annual installments equally on 31 May 2022 to 31 May 2026.

35. Log/Serial Number of the previous form:

36. Number of concert party document(s) under section 317 attached/uploaded:

Date of filing this Form 3A:

29/11/2021
(dd/mm/yyyy)